Delivering safer immunotherapies for cancer
Name
1-s2.0-S0169409X17300674-main.pdf
Size
2.18 MB
Format
Adobe PDF
Checksum (MD5)
8da93c2d9d4237da2f69e3380df68e84
Author(s)
Milling, Lauren Elizabeth
Irvine, Darrell J
Zhang, Yuan, Ph. D. Massachusetts Institute of Technology
Date Issued
May 2017
Journal
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Citation
Milling, Lauren et al “Delivering Safer Immunotherapies for Cancer.” Advanced Drug Delivery Reviews 114 (May 2017): 79–101 © 2017 The Authors
Version
Final published version
Abstract
Cancer immunotherapy is now a powerful clinical reality, with a steady progression of new drug approvals and a massive pipeline of additional treatments in clinical and preclinical development. However, modulation of the immune system can be a double-edged sword: Drugs that activate immune effectors are prone to serious non-specific systemic inflammation and autoimmune side effects. Drug delivery technologies have an important role to play in harnessing the power of immune therapeutics while avoiding on-target/off-tumor toxicities. Here we review mechanisms of toxicity for clinically-relevant immunotherapeutics, and discuss approaches based in drug delivery technology to enhance the safety and potency of these treatments. These include strategies to merge drug delivery with adoptive cellular therapies, targeting immunotherapies to tumors or select immune cells, and localizing therapeutics intratumorally. Rational design employing lessons learned from the drug delivery and nanomedicine fields has the potential to facilitate immunotherapy reaching its full potential.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.ADDR.2017.05.011
